On May 17, 2023, Mind Medicine (MindMed) Inc. announced that the Company has enrolled more than 50% of patients in its Phase 2b clinical trial evaluating MM-120 (lysergide D-tartrate) for generalized anxiety disorder (GAD). In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. As disclosed in the Press Release, the Phase 2b trial in patients diagnosed with GAD is a multi-center, parallel, randomized, double-blind, placebo-controlled, dose-optimization study.

The trial plans to enroll up to 200 participants who will be randomized to receive a single administration of 25 g, 50 g, 100 g or 200 g of MM-120 or placebo.